Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20-positive Non-Hodgkin Lymphoma”

106 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 106 results

Testing effectiveness (Phase 2)Looking for participantsNCT06021678
What this trial is testing

Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

Who this might be right for
CD20-positive Non-Hodgkin Lymphoma
Guangzhou Excelmab Inc. 415
Testing effectiveness (Phase 2)Study completedNCT00169143
What this trial is testing

Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma

Who this might be right for
Untreated CD20-positive Large B-cell Lymphoma
Lymphoma Study Association 60
Testing effectiveness (Phase 2)Study completedNCT01015248
What this trial is testing

Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Who this might be right for
MALT LYMPHOMA
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 60
Early research (Phase 1)Ended earlyNCT06248086
What this trial is testing

Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

Who this might be right for
B-cell Lymphoma
Astellas Pharma Global Development, Inc. 1
Testing effectiveness (Phase 2)Ended earlyNCT00250861
What this trial is testing

Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
US Oncology Research 110
Testing effectiveness (Phase 2)Study completedNCT00070018
What this trial is testing

S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
SWOG Cancer Research Network 46
Testing effectiveness (Phase 2)Study completedNCT00290667
What this trial is testing

Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Who this might be right for
Lymphoma
German High-Grade Non-Hodgkin's Lymphoma Study Group 586
Large-scale testing (Phase 3)Ended earlyNCT00384111
What this trial is testing

Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)

Who this might be right for
Follicular LymphomaLymphoma, Follicular
Spectrum Pharmaceuticals, Inc 26
Testing effectiveness (Phase 2)Study completedNCT00048737
What this trial is testing

Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

Who this might be right for
LymphomaLeukemia
M.D. Anderson Cancer Center 70
Early research (Phase 1)Study completedNCT02945215
What this trial is testing

Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

Who this might be right for
B-Cell Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 181
Testing effectiveness (Phase 2)Ended earlyNCT03578198
What this trial is testing

Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)

Who this might be right for
CD20-positive Non-Hodgkin Lymphoma
Seoul National University Hospital 12
Early research (Phase 1)Study completedNCT03057418
What this trial is testing

Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim

Who this might be right for
Lymphoma, Non-HodgkinLymphoma, Follicular
Biointegrator LLC 7
Testing effectiveness (Phase 2)UnknownNCT04425824
What this trial is testing

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell LymphomaRituximabToripalimab
Chinese Academy of Medical Sciences 20
Early research (Phase 1)Study completedNCT04103905
What this trial is testing

MIL62 in Treatment of CD20 Positive B-cell Lymphomas

Who this might be right for
CD20-positive B Cell Non-Hodgkin Lymphoma
Beijing Mabworks Biotech Co., Ltd. 27
Testing effectiveness (Phase 2)Study completedNCT00244855
What this trial is testing

Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma

Who this might be right for
Contiguous Stage II Grade 1 Follicular LymphomaContiguous Stage II Grade 2 Follicular LymphomaContiguous Stage II Marginal Zone Lymphoma+20 more
Fred Hutchinson Cancer Center 32
Testing effectiveness (Phase 2)Ended earlyNCT00077961
What this trial is testing

Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

Who this might be right for
Non-Hodgkin's Lymphoma
Genzyme, a Sanofi Company 49
Testing effectiveness (Phase 2)Temporarily pausedNCT03704714
What this trial is testing

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Who this might be right for
Aggressive Non-Hodgkin LymphomaB-Cell Non-Hodgkin LymphomaCD20 Positive+5 more
Northwestern University 30
Testing effectiveness (Phase 2)Study completedNCT03458260
What this trial is testing

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Who this might be right for
Aggressive Non-Hodgkin Lymphoma
The Lymphoma Academic Research Organisation 74
Testing effectiveness (Phase 2)UnknownNCT00385125
What this trial is testing

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Who this might be right for
Lymphoma, High-Grade
University of Magdeburg 30
Early research (Phase 1)Looking for participantsNCT07073833
What this trial is testing

The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma

Who this might be right for
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Imbioray (Hangzhou) Biomedicine Co., Ltd. 40
Load More Results